Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Understanding what happens when you stop GHK-Cu helps you plan maintenance strategies
Pregnancy with portal hypertension
Introduction We focused on the stable gastric pentadecapeptide BPC 157 ( Thus, we suggest that one single application of the NO-synthase (NOS) blocker N(G)-nitro-L-arginine methyl ester (L-NAME) may induce retinal ischemia in rats, and that the stable pentadecapeptide BPC 157 may be the therapy, since it may interact with the NO-system and may counteract various adverse effects of L-NAME application (see In the previous eye research studies, BPC 157 counteracts atropine-mydriasis, but it also opposes an immediate and hour-lasting miotic effect of L-NAME in rats and guinea pigs, and participates in pupil control potentially via NO-mediated and cholinergic mechanisms ( This may be essential for the effective counteraction of the damaging effect of the retrobulbar L-NAME application
BPC-157 has a strong safety profile in research literature with minimal reported side effects at therapeutic doses
Peptides are fragile chains of amino acids
